ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 507
- Registration Number
- NCT04542499
- Locations
- 🇷🇸
Belgrade, Belgrade, Serbia
🇷🇸Belgrade, Kragujevac, Belgrade, Serbia
🇪🇸Elche, Elche, Alicante, Spain
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
- Conditions
- Ankylosing Spondylitis (AS)Rheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)Atopic Dermatitis (AD)
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3600
- Registration Number
- NCT04541810
- Locations
- 🇰🇷
Inje University - Busan Paik Hospital /ID# 259143, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Kyungpook National University Hospital /ID# 251294, 중구, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷Kyungpook National University Hospital /ID# 251305, 중구, Daegu Gwang Yeogsi, Korea, Republic of
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
- Conditions
- Crohn's Disease (CD)
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 527
- Registration Number
- NCT04524611
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena /ID# 223315, Sevilla, Spain
🇪🇸Hospital Clinico Universitario de Valencia /ID# 223321, Valencia, Spain
🇨🇦Axler, Toronto, ON. Canada /ID# 223740, Toronto, Ontario, Canada
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- Genetic: RGX-314 Dose 3Genetic: RGX-314 Dose 1Genetic: RGX-314 Dose 2Biological: RanibizumabDrug: Local SteroidDrug: Topical Steroid
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 115
- Registration Number
- NCT04514653
- Locations
- 🇺🇸
Bakersfield Location, Bakersfield, California, United States
🇺🇸Baltimore Location, Baltimore, Maryland, United States
🇺🇸Boston Location, Boston, Massachusetts, United States
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 14
- Registration Number
- NCT04509622
- Locations
- 🇯🇵
NTT Medical Center Tokyo /ID# 223574, Shinagawa-ku, Tokyo, Japan
🇯🇵Okayama University Hospital /ID# 222990, Okayama-shi, Okayama, Japan
🇯🇵NHO Nagoya Medical Center /ID# 223671, Nagoya-shi, Aichi, Japan
Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel
- Conditions
- Parkinson's Disease
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT04500106
- Locations
- 🇮🇱
The Chaim Sheba Medical Center /ID# 222470, Ramat Gan, Tel-Aviv, Israel
🇮🇱Kaplan Medical Center /ID# 222753, Rehovot, Israel
🇦🇺Kingston Centre /ID# 222563, Cheltenham, Victoria, Australia
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 96
- Registration Number
- NCT04499248
- Locations
- 🇺🇸
Logan Ophthalmic Research Inc. /ID# 252087, Tamarac, Florida, United States
🇺🇸Coastal Research Associates /ID# 234649, Roswell, Georgia, United States
🇺🇸Horizon Eye Specialists & Lasik Center - Sun City /ID# 252153, Sun City, Arizona, United States
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis (RA)
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1532
- Registration Number
- NCT04497597
- Locations
- 🇮🇱
Hillel Yaffe Medical Center /ID# 222170, Hadera, H_efa, Israel
🇮🇱Rambam Health Care Campus /ID# 222118, Haifa, H_efa, Israel
🇮🇱Galilee Medical Center /ID# 222113, Nahariya, HaTsafon, Israel
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 518
- Registration Number
- NCT04492020
- Locations
- 🇺🇸
WR-ClinSearch /ID# 238287, Chattanooga, Tennessee, United States
🇺🇸Tidewater Integr Med Research /ID# 236867, Virginia Beach, Virginia, United States
🇺🇸Wr-Pri Llc /Id# 236007, Los Alamitos, California, United States
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Myelofibrosis (MF)
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1
- Registration Number
- NCT04480086
- Locations
- 🇺🇸
Stony Brook University Hospital /ID# 222653, Stony Brook, New York, United States
🇰🇷Inje University Busan Paik Hospital /ID# 224043, Busan, Korea, Republic of
🇺🇸UC Health - Cincinnati /ID# 224079, Cincinnati, Ohio, United States